Toronto Innovation Acceleration Partners has scored an exit having invested at least twice in cancer and fibrosis therapy developer Forbius.

Pharmaceutical firm Bristol Myers Squibb (BMS) has paid an undisclosed sum to acquire Forbius, a US-based cancer and fibrosis drug developer backed by multi-university commercialisation firm Toronto Innovation Acceleration Partners (TIAP). The deal will close in the fourth quarter of 2020 once customary closing conditions have been met. The deal consists of an upfront and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.